|
Median age, years (range)
|
60.0 (42, 82)
|
|
Patient age, n (%)
|
|
≥65
|
32 (39.0)
|
|
Gender, n (%)
|
|
Male
|
43 (52.4)
|
|
Female
|
39 (47.6)
|
|
Baseline ECOG performance status, n (%)
|
|
0
|
26 (31.7)
|
|
1
|
54 (65.9)
|
|
2
|
2 (2.4)
|
|
Tumor burden increase (screening to pre-dose), n (%)
|
60 (73.2)
|
|
Median, %
|
23.1
|
|
Range, %
|
2.1–317.9
|
|
MM subtype at baseline, n (%)
|
|
IgG
|
40 (48.8)
|
|
IgA
|
17 (20.7)
|
|
IgD
|
7 (8.5)
|
|
Others
|
19 (23.2)
|
|
R-ISS stage at baseline, n (%)
|
|
I
|
23 (28.0)
|
|
II
|
50 (61.0)
|
|
III
|
9 (11.0)
|
|
High-risk cytogenetic abnormalities
|
55 (67.1)
|
|
del 17p13
|
18 (22.0)
|
|
t(4;14)
|
21 (25.6)
|
|
t(14;16)
|
5 (6.1)
|
|
1q amplification
|
53 (64.6)
|
|
Creatinine clearance, mL/min, n (%)
|
|
<30
|
3 (3.7)
|
|
30–<60
|
15 (18.3)
|
|
≥60
|
64 (78.0)
|
|
Median time since initial MM diagnosis, years (range)
|
3.2 (0.2–13.4)
|
|
Respond to last regimen (≥PR), n (%)
|
24 (29.3)
|
|
Median prior regimens (range)
|
5 (1–16)
|
|
Prior therapy, n (%)
|
|
Lenalidomide
|
|
Exposed vs refractory
|
82 (100.0) vs 82 (100.0)
|
|
Bortezomib
|
|
Exposed vs refractory
|
82 (100.0) vs 82 (100.0)
|
|
Daratumumab
|
|
Exposed vs refractory
|
23 (28.0) vs 20 (24.4)
|
|
Ixazomib
|
|
Exposed vs refractory
|
28 (34.1) vs 26 (31.7)
|
|
Carfilzomib
|
|
Exposed vs refractory
|
6 (7.3) vs 5 (6.1)
|
|
Pomalidomide
|
|
Exposed vs refractory
|
10 (12.2) vs 9 (11.0)
|
|
Prior ASCT
|
18 (22.0)
|
|
Prior CAR-T
|
10 (12.2)
|
